JP2013511566A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511566A5
JP2013511566A5 JP2012540414A JP2012540414A JP2013511566A5 JP 2013511566 A5 JP2013511566 A5 JP 2013511566A5 JP 2012540414 A JP2012540414 A JP 2012540414A JP 2012540414 A JP2012540414 A JP 2012540414A JP 2013511566 A5 JP2013511566 A5 JP 2013511566A5
Authority
JP
Japan
Prior art keywords
protein
factor
pegylated protein
buffer
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012540414A
Other languages
English (en)
Japanese (ja)
Other versions
JP5827955B2 (ja
JP2013511566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/068112 external-priority patent/WO2011064247A1/en
Publication of JP2013511566A publication Critical patent/JP2013511566A/ja
Publication of JP2013511566A5 publication Critical patent/JP2013511566A5/ja
Application granted granted Critical
Publication of JP5827955B2 publication Critical patent/JP5827955B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012540414A 2009-11-24 2010-11-24 Peg化タンパク質の精製方法 Active JP5827955B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09176881.2 2009-11-24
EP09176881 2009-11-24
US26448609P 2009-11-25 2009-11-25
US61/264,486 2009-11-25
PCT/EP2010/068112 WO2011064247A1 (en) 2009-11-24 2010-11-24 Method of purifying pegylated proteins

Publications (3)

Publication Number Publication Date
JP2013511566A JP2013511566A (ja) 2013-04-04
JP2013511566A5 true JP2013511566A5 (cg-RX-API-DMAC7.html) 2014-01-16
JP5827955B2 JP5827955B2 (ja) 2015-12-02

Family

ID=41401820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540414A Active JP5827955B2 (ja) 2009-11-24 2010-11-24 Peg化タンパク質の精製方法

Country Status (5)

Country Link
US (1) US8697844B2 (cg-RX-API-DMAC7.html)
EP (1) EP2504349B1 (cg-RX-API-DMAC7.html)
JP (1) JP5827955B2 (cg-RX-API-DMAC7.html)
CN (2) CN107383158A (cg-RX-API-DMAC7.html)
WO (1) WO2011064247A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 血液凝固タンパク質複合体
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
EP3731871B1 (en) * 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
EP3731872B1 (en) 2017-12-29 2021-11-24 F. Hoffmann-La Roche AG Process for providing pegylated protein composition
US20200362002A1 (en) * 2017-12-29 2020-11-19 Hoffmann-La Roche Inc. Process for providing pegylated protein composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
WO1996040731A1 (en) * 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
DE69907439T3 (de) * 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
EP1084136B1 (en) 1998-06-01 2004-08-25 Genentech, Inc. Separation of antibody monomers from its multimers by use of ion-exchange chromatography
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US7470779B2 (en) * 2002-09-20 2008-12-30 Pfizer Inc. Process for decreasing aggregate levels of pegylated protein
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
AU2004296860B2 (en) * 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
BRPI0614839A2 (pt) * 2005-08-19 2009-05-19 Neose Technologies Inc fator vii e fator viia glicopeguilados
DK2125866T3 (da) 2007-02-28 2013-07-29 Baxter Int Fremgangsmåde til rensning af rekombinant blodkoagulationsfaktor IX, som er beriget med sulfaterede og/eller phosphorylerede molekyler
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix

Similar Documents

Publication Publication Date Title
JP2013511566A5 (cg-RX-API-DMAC7.html)
JP2013514073A5 (cg-RX-API-DMAC7.html)
EA201171199A1 (ru) Способ очистки рекомбинантного фсг
ES2923018T3 (es) Métodos de purificación de ARN
BR112013030628A2 (pt) "métodos para produção de uma proteína purificada de interesse utilizando uma matriz de cromatografia de afinidade (ca), e de um anticorpo purificado, fragmento de anticorpo ou proteína de fusão de fc utilizando a coluna de proteína a".
JP2011525523A5 (cg-RX-API-DMAC7.html)
JP2012018171A5 (cg-RX-API-DMAC7.html)
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
JP2013500711A5 (cg-RX-API-DMAC7.html)
JP2011510303A5 (cg-RX-API-DMAC7.html)
JP2016519137A5 (cg-RX-API-DMAC7.html)
JP2008505133A5 (cg-RX-API-DMAC7.html)
JP2012518034A5 (cg-RX-API-DMAC7.html)
JP2013528183A5 (cg-RX-API-DMAC7.html)
JP2008508859A5 (cg-RX-API-DMAC7.html)
GB2443505B (en) Nucleic acid purification method
JP2013503877A5 (cg-RX-API-DMAC7.html)
RU2014111820A (ru) Способы элиминации вируса
WO2010151632A8 (en) Protein purification by caprylic acid (octanoic acid ) precipitation
JP2014507368A5 (cg-RX-API-DMAC7.html)
RU2011125656A (ru) Очистка полипептидов
JP2014506874A5 (cg-RX-API-DMAC7.html)
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
CN103725664A (zh) 一种高度纯化激肽释放酶的方法
TWI679209B (zh) 使用陽離子交換層析法純化同功抗體之方法